A Phase 1 interventional study of Lentiviral vector transduced CD34+ cells in Severe Combined Immunodeficiency, X-Linked, sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to male participants aged 8 Weeks to 5 Years. Per ClinicalTrials.gov, last updated 2023-10-12.
Sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both cellular and humoral immunity. SCID arises from a variety of molecular defects which affect lymphocyte development and function. The most common form of SCID is an X-linked form (SCID-X1), which accounts for 30-50% of all cases. SCID-X1 is caused by defects in the common cytokine receptor gamma chain, which was originally identified as a component of the high affinity interleukin-2 receptor (IL2RG).
Allogeneic haematopoietic stem cell transplantation (HSCT), which replaces the patient's bone marrow with that of a healthy donor, is the only treatment that definitively restores the normal function of the bone marrow. HSCT is the first choice of treatment for patients with signs of bone marrow failure and a fully-matched related donor. However, patients without a fully-matched related donor have much worse overall outcomes from HSCT.
This study will investigate whether patients with SCID-X1 without a fully matched related donor may benefit from gene therapy. To do this the investigators propose to perform a phase I/II clinical trial to evaluate the safety and efficacy (effect) of gene therapy for SCID-X1 patients using a lentivirus delivery system containing the IL2RG gene. Up to 5 eligible SCID-X1 patients will undergo mobilisation and harvest of their haematopoietic stem precursor cells (HPSCs). In the laboratory the disabled lentivirus will be used to insert a normal human IL2RG gene into the patient's harvested HPSCs. Patients will receive chemotherapy conditioning prior to cell infusion, in order to enhance grafting. The genetically corrected stem cells will then be re-infused into the patient. Patients will be followed up for 2 years. This trial will determine whether gene therapy for SCID-X1 using a lentiviral vector is safe, feasible and effective
28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.
This study's planned enrollment of 5 is below the median of 9 across 16 interventional studies indexed under X-Linked Combined Immunodeficiency Diseases.
Browse X-Linked Combined Immunodeficiency Diseases studies →Great Ormond Street Hospital for Children NHS Foundation Trust is the lead sponsor of 82 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with an active, therapy-resistant infection. Infections that are known to be highly morbid in SCID patients will be considered active and therapy-resistant if the infectious agent is repeatedly isolated despite a minimum of 2 weeks of appropriate therapy and is associated with significant organ dysfunction (including but not limited to abnormalities listed below).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
Drug: Lentiviral vector transduced CD34+ cells
Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
Also known as: G2SCID lentiviral vector transduced CD34+ cells
Measure event-free survival after 1 year after gene transfer
Event-free survival at 1 year post-infusion. Events will include death, infusion of unmanipulated back-up product for failure of haematopoietic recovery, and allogeneic transplant performed for poor immune reconstitution
Time frame: 1 year
Measure T cell immune reconstitution: CD3+ T cell count
T cell reconstitution at 1 year post-infusion: CD3+ T cell count ≥300 cells/microliter in peripheral blood
Time frame: 1 year
Measure T cell immune reconstitution; gene marking
T cell reconstitution at 1 year post-infusion: Gene marking ≥0.1 copies/cell in sorted CD3+ T cells
Time frame: 1 year
Measure overall survival
Measure overall survival at 2 years post-infusion
Time frame: 2 years
Measure event-free survival
Measure event-free survival at 2 years post-infusion
Time frame: 2 years
Incidence of adverse events related to gene therapy
Incidence of adverse events related to gene therapy
Time frame: up to 2 years post-infusion of gene therapy
Enumeration of absolute lymphocyte count determined by routine complete reconstitution
Enumeration of absolute lymphocyte count determined by routine complete blood counts (CBC)
Time frame: up to 2 years post-infusion of gene therapy
Haematopoietic recovery after receipt of busulfan
Haematopoietic recovery is defined as absolute neutrophil count above 0.5 x10\^9 /l for three consecutive days, achieved within 6 weeks following infusion.
Time frame: up to 6 weeks post-infusion of gene therapy
Measure absolute numbers of T, B and NK lymphocytes
Absolute numbers of T, B and NK lymphocytes
Time frame: up to 2 years post-infusion of gene therapy
Calculate percentage of naïve and memory T cell subsets
Percentage of naïve and memory T cell subsets
Time frame: up to 2 years post-infusion of gene therapy
Measure laboratory results which correlates with efficacious immune reconstitution
Percentage of naïve and memory B cell subsets
Time frame: up to 2 years post-infusion of gene therapy
Determine Freedom from immunoglobulin substitution for at least 9 months
Freedom from immunoglobulin substitution for at least 9 months
Time frame: 2 years post-infusion of gene therapy
Measure serum immunoglobulin levels reconstitution
Serum immunoglobulin levels
Time frame: up to 2 years post-infusion of gene therapy
Measure proliferation of lymphocytes to phytohaemagglutinin determined by titrated thymidine incorporation reconstitution
Proliferation of lymphocytes to phytohaemagglutinin determined by titrated thymidine incorporation
Time frame: up to 2 years post-infusion of gene therapy
Measure antigen specific antibody titres to tetanus toxoid reconstitution
Measure antigen specific antibody titres to tetanus toxoid
Time frame: up to 2 years post-infusion of gene therapy
Measure T cell receptor excision circles (TREC)
Measure T cell receptor excision circles (TREC)
Time frame: up to 2 years post-infusion of gene therapy
Measure T cell receptor Vb family usage
Measure T cell receptor Vb family usage
Time frame: up to 2 years post-infusion of gene therapy
To assess the efficacy of stem cell transduction/engraftment by measuring the frequency of gene marking in peripheral blood cells
Gene marking in specific lineages of peripheral blood cells. Genomic DNA isolated from each population will be assayed for VCN by quantitative PCR (qPCR). The results will be aggregated to determine the effectiveness of gene marking in the peripheral blood cells.
Time frame: up to 2 years post-infusion of gene therapy
Measure clonal diversity of vector integrants
Clonal diversity will be quantitated and used to estimate the number of transduced haematopoietic stem cells that have engrafted in the subjects. Number of sequence reads and unique integration sites will be assessed to quantify population clone diversity, distribution of integration sites and relative abundance.
Time frame: up to 2 years post-infusion of gene therapy
Correlation of potential biomarkers of humoral immune reconstitution with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post infusion including: Gene marking in B cells and B cell phenotype.
Correlation of potential biomarkers of humoral immune reconstitution at 6 months, 1 year, 2 years post infusion with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post infusion including: Gene marking in B cells and B cell phenotype.
Time frame: at 6 month, 12 month and 2 years post-infusion of gene therapy
Correlation of busulfan area-under-the-curve measurements prior to infusion with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post-infusion and other markers of humoral immune reconstitution
Correlation of busulfan area-under-the-curve measurements prior to infusion with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post-infusion and other markers of humoral immune reconstitution
Time frame: 2 years post-infusion of gene therapy
Evidence of insertion site sharing between 2 or more lineages at 1 year and 2 years post infusion
Evidence of insertion site sharing between 2 or more lineages at 1 year and 2 years post infusion
Time frame: 1 year and 2 years post infusion of gene therapy
Correlation of gene marking and insertion site sharing in expanded peripheral blood CD34+ cells with peripheral blood mature cell samples at 1 year and 2 years post infusion
Correlation of gene marking and insertion site sharing in expanded peripheral blood CD34+ cells with peripheral blood mature cell samples at 1 year and 2 years post infusion
Time frame: 1 year and 2 years post infusion of gene therapy
Description of T cell receptor and B cell receptor repertoire before and after infusion
Description of T cell receptor and B cell receptor repertoire before and after infusion
Time frame: Pre-harvest, 3 month, 6 month, 12 month and 2 years post infusion of gene therapy
Description of NK cell function and phenotype before and after infusion
Description of NK cell function and phenotype before and after infusion
Time frame: Pre-harvest, 3 month, 6 month, 12 month and 2 years post infusion of gene therapy
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2018 (actual). Primary completion is estimated for Aug 2026, 92 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
X-Linked Combined Immunodeficiency Diseases →
Great Ormond Street Hospital for Children NHS Foundation Trust